FTC commissioners dig into Impax settlement

The Federal Trade Commission’s members have questioned both sides about the balance of costs and benefits in Impax Laboratories’ reverse-payment settlement with Endo Pharmaceuticals – in the first oral arguments hearing since the agency added five new members.

Get unlimited access to all Global Competition Review content